Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial

Overview

The purpose of this study is to determine whether prize-based contingency management (prizeCM) combined with cognitive behavioral therapy (CBT) is more effective in the treatment of of cocaine-dependent patients compared to CBT only. Patients were randomized to prizeCM + CBT (experimental group) or to CBT (control group) an treated over 24 weeks. It is the first trial of this type in Europe.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: August 2013

Interventions

  • Behavioral: Cognitive behavioral therapy (CBT)

Arms, Groups and Cohorts

  • Experimental: 1
    • Cognitive behavioral therapy (CBT) + prize-based contingency management (prizeCM)
  • Active Comparator: 2
    • Cognitive behavioral therapy (CBT)

Clinical Trial Outcome Measures

Primary Measures

  • retention in treatment, cocaine abstinence
    • Time Frame: 24 weeks
    • cocaine abstinence: at least 3 consecutive weeks of cocaine abstinence, the maximum number of weeks of continous abstinence and proportions of cocaine-free urine samples during the entire 24-week and at 6-month follow-up.

Secondary Measures

  • patients’ satisfaction with the therapy, clinical measures
    • Time Frame: 24 weeks
    • patients’ satisfaction with prize-based contingency management and with CBT

Participating in This Clinical Trial

Inclusion Criteria

  • cocaine dependence, aged 18 or older, other dependences Exclusion Criteria:

  • severe somatic, brain, or psychiatric disease, attention deficit disorders with medication methylphenidate

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Basel, Switzerland
  • Provider of Information About this Clinical Study
    • Principal Investigator: Sylvie Petitjean, Dr. phil – University Hospital, Basel, Switzerland
  • Overall Official(s)
    • Sylvie A Petitjean, Dr. phil., Principal Investigator, Psychiatric Hospital of the University of Basel

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.